Alemtuzumab is not superior to basiliximab to prevent acute antibody-mediated rejection (AMR) after simultaneous pancreas-kidney transplantation
Publication
, Conference
Pirsch, JD; Pascual, J; Sasmaniego, MD; Torrealba, JR; Odorico, JS; Becker, YT; Fernandez, LA; Knechtle, SJ; Sollinger, HW
Published in: XENOTRANSPLANTATION
September 1, 2007
Duke Scholars
Published In
XENOTRANSPLANTATION
ISSN
0908-665X
Publication Date
September 1, 2007
Volume
14
Issue
5
Start / End Page
381 / 381
Location
Minneapolis, MN
Publisher
BLACKWELL PUBLISHING
Conference Name
Joint Meeting of the International-Xenotransplantation-Association/International-Pancrcas-and-Islet-Transplant-Association/Cell-Transplant-Society
Related Subject Headings
- Surgery
- 3202 Clinical sciences
- 1103 Clinical Sciences
Citation
APA
Chicago
ICMJE
MLA
NLM
Pirsch, J. D., Pascual, J., Sasmaniego, M. D., Torrealba, J. R., Odorico, J. S., Becker, Y. T., … Sollinger, H. W. (2007). Alemtuzumab is not superior to basiliximab to prevent acute antibody-mediated rejection (AMR) after simultaneous pancreas-kidney transplantation. In XENOTRANSPLANTATION (Vol. 14, pp. 381–381). Minneapolis, MN: BLACKWELL PUBLISHING.
Pirsch, John D., Julio Pascual, Milagros D. Sasmaniego, Jose R. Torrealba, Jon S. Odorico, Yolanda T. Becker, Luis A. Fernandez, Stuart J. Knechtle, and Hans W. Sollinger. “Alemtuzumab is not superior to basiliximab to prevent acute antibody-mediated rejection (AMR) after simultaneous pancreas-kidney transplantation.” In XENOTRANSPLANTATION, 14:381–381. BLACKWELL PUBLISHING, 2007.
Pirsch JD, Pascual J, Sasmaniego MD, Torrealba JR, Odorico JS, Becker YT, et al. Alemtuzumab is not superior to basiliximab to prevent acute antibody-mediated rejection (AMR) after simultaneous pancreas-kidney transplantation. In: XENOTRANSPLANTATION. BLACKWELL PUBLISHING; 2007. p. 381–381.
Pirsch, John D., et al. “Alemtuzumab is not superior to basiliximab to prevent acute antibody-mediated rejection (AMR) after simultaneous pancreas-kidney transplantation.” XENOTRANSPLANTATION, vol. 14, no. 5, BLACKWELL PUBLISHING, 2007, pp. 381–381.
Pirsch JD, Pascual J, Sasmaniego MD, Torrealba JR, Odorico JS, Becker YT, Fernandez LA, Knechtle SJ, Sollinger HW. Alemtuzumab is not superior to basiliximab to prevent acute antibody-mediated rejection (AMR) after simultaneous pancreas-kidney transplantation. XENOTRANSPLANTATION. BLACKWELL PUBLISHING; 2007. p. 381–381.
Published In
XENOTRANSPLANTATION
ISSN
0908-665X
Publication Date
September 1, 2007
Volume
14
Issue
5
Start / End Page
381 / 381
Location
Minneapolis, MN
Publisher
BLACKWELL PUBLISHING
Conference Name
Joint Meeting of the International-Xenotransplantation-Association/International-Pancrcas-and-Islet-Transplant-Association/Cell-Transplant-Society
Related Subject Headings
- Surgery
- 3202 Clinical sciences
- 1103 Clinical Sciences